Tharimmune to Acquire Bio-Genetics for $1.5M
Ticker: CNTN · Form: 8-K · Filed: Jun 11, 2024 · CIK: 1861657
| Field | Detail |
|---|---|
| Company | Tharimmune, INC. (CNTN) |
| Form Type | 8-K |
| Filed Date | Jun 11, 2024 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: acquisition, biotechnology, merger
TL;DR
Tharimmune buying Bio-Genetics for $1.5M, closing Q3.
AI Summary
Tharimmune, Inc. announced on June 11, 2024, that it has entered into a definitive agreement to acquire all outstanding equity interests in Bio-Genetics, Inc. for an aggregate purchase price of $1.5 million. The transaction is expected to close in the third quarter of 2024, subject to customary closing conditions.
Why It Matters
This acquisition could expand Tharimmune's pipeline and market presence in the biotechnology sector.
Risk Assessment
Risk Level: medium — Acquisitions carry inherent risks, including integration challenges and the possibility that the acquired company's assets may not perform as expected.
Key Numbers
- $1.5M — Acquisition Price (Total cost for acquiring Bio-Genetics, Inc.)
Key Players & Entities
- Tharimmune, Inc. (company) — Acquiring company
- Bio-Genetics, Inc. (company) — Acquired company
- $1.5 million (dollar_amount) — Aggregate purchase price
- June 11, 2024 (date) — Announcement date
- third quarter of 2024 (date) — Expected closing period
FAQ
What is the primary strategic rationale behind Tharimmune's acquisition of Bio-Genetics, Inc.?
The filing does not explicitly state the strategic rationale, but acquisitions typically aim to expand product pipelines, enter new markets, or acquire new technologies.
What are the key closing conditions for the acquisition of Bio-Genetics, Inc.?
The acquisition is subject to customary closing conditions, which are not detailed in this filing.
Has Tharimmune, Inc. previously undergone a name change?
Yes, Tharimmune, Inc. was formerly known as Hillstream BioPharma Inc. until a name change on September 25, 2023.
What is the principal executive office address for Tharimmune, Inc.?
The principal executive offices are located at 1200 Route 22 East, Suite 2000, Bridgewater, NJ 08807.
What is the expected closing timeframe for the Bio-Genetics, Inc. acquisition?
The transaction is expected to close in the third quarter of 2024.
Filing Stats: 444 words · 2 min read · ~1 pages · Grade level 12 · Accepted 2024-06-11 16:15:32
Key Financial Figures
- $0.0001 — nge on which registered Common stock, $0.0001 par value THAR The Nasdaq Stock Mar
Filing Documents
- form8-k.htm (8-K) — 34KB
- 0001493152-24-023474.txt ( ) — 205KB
- thar-20240611.xsd (EX-101.SCH) — 3KB
- thar-20240611_lab.xml (EX-101.LAB) — 33KB
- thar-20240611_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: June 11, 2024 Tharimmune, Inc. /s/ Randy Milby Randy Milby Chief Executive Officer -3-